---
document_datetime: 2023-09-21 19:12:31
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/leukoscan-epar-procedural-steps-taken-authorisation_en.pdf
document_name: leukoscan-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5809243
conversion_datetime: 2025-12-26 19:48:44.94716
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Immunomedics B. V., Netherlands, submitted on 31 July 1995 to the European Agency for the Evaluation of Medicinal Products (EMEA) an application to obtain a marketing authorisation in  accordance  with  the  Centralised  Procedure  for  the  medicinal  product  LeukoScan  (Sulesomab) falling within the scope of Part A of the Annex to Council Regulation EEC No. 2309/93.

•

- On the basis of Pharmacia's responses dated 29 April 1996 to the Inspector's questions put on 14 March 1996, the outstanding issues have finally been resolved.

The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Prof. R. Kurth Co-Rapporteur: Dr. D. Jefferys Licensing status: LeukoScan  has  no  previous  marketing  authorisations  and  no  pending,  rejected,  withdrawn  or suspended applications. 2. Steps taken for the assessment of the product · During  the  CPMP  meeting  on  21-22  November  1995,  the  Rapporteur  and  Co-rapporteur identified the major concerns in Parts II and III of the dossier. · The Rapporteur's initial assessment report was circulated to all the members of the CPMP on 12 December 1995. · The Co-rapporteur's initial assessment report was circulated to all the members of the CPMP on 10 December 1995. · The Biotechnology Working Party (BWP) during their meeting on 8-9 January 1996 agreed on the draft list of questions on Part II (Biological and pharmaceutical aspects) for finalisation by the CPMP. · The CPMP during their meeting on  16-18  January  1996,  finalised  the  list  of  questions  to  be addressed by the company. · The CPMP consolidated list of questions was sent to the company on 17 January 1996 (Stop of the clock). · Inspections of the Immunomedics  Inc.  Facilities at Newark,  NJ,  USA  took  place on 22-24  January  1996,  and  indicated  major  deficiencies  and  failures  to  comply  with  Good Manufacturing Practice (GMP) standards. It was also pointed out that the importing company of LeukoScan in the European Economic Area (EEA) has to be determined and a Site Master File should be forwarded the following 3 months. · Inspections of Pharmacia Inc., Facilities, Albuquerque, USA took place on 25-26 January 1996, and indicated major deficiencies and failures to comply with GMP standards. Pharmacia's  response  to  the  inspections  issues,  dated  28  February  1996,  was  considered inadequate and additional data were requested on 6 March 1996. After reviewing the company's response of. 8 March 1996, the CPMP concluded that the GMP issues have not been resolved and a re-inspection was recommended before the finalisation of the CPMP scientific evaluation. The above conclusion was sent to Pharmacia on 14 March 1996. Medicinal product no longer authorised

- The  applicant  submitted  the  responses  to  the  consolidated  CPMP  list  of  questions  on 19 July 1996 and the clock restarted.

<div style=\"page-break-after: always\"></div>

- After a meeting that took place between Rapporteur and Co-Rapporteur on 4 September 1996, the applicant was asked to submit additional details on quality issues.
- The Rapporteur/Co-Rapporteur the responses' assessment report and joint recommendation was circulated to CPMP members on 16 September 1996.
- The inspector confirmed on 3 October 1996 that the remaining GMP issues were solved.
- The  Company  presented  for  a  hearing  at  the  BWP  meeting  on  7  October  1996  to  discuss outstanding  biopharmaceutical  points.  The  BWP  prepared  a  recommendation  for  the  CPMP consideration at their meeting on 15 October 1996. · The CPMP during its meeting on 15-17 October 1996 on the basis of the favourable benefit-risk assessment issued a positive opinion for granting a marketing authorisation to LeukoScan. Medicinal product no longer authorised